期刊文献+

伊贝沙坦治疗老年高血压病

Efficacy of Irbesartan in Gerontal Patients with Hypertension
下载PDF
导出
摘要 目的 观察伊贝沙坦和卡托普利对老年原发性高血压患者的降压作用及内生肌酐清除率 (Cr-C)的影响。方法 选择 6 8例老年原发性高血压患者 ,Cr -C在 5 0 .0ml± 19.4ml/ (min·1.73m2 ) - 1之间。随机分成伊贝沙坦组 (n =34)、卡托普利组 (n =34) ,对 2组分别进行治疗前、后降压幅度、Cr -C的比较。结果 伊贝沙坦和卡托普利对于老年原发性高血压的降压作用同样有效 ,但前者提高Cr-C的作用明显优于后者 ,2组比较有显著差异性 (P <0 .0 1)。伊贝沙坦组未见干咳现象 ,卡托普利组干咳发生率为 17.6 %。结论 伊贝沙坦不仅有良好的降压作用 ,还能较卡托普利更好地提高Cr-C、改善肾功。 Objective To investigate the antihypertensive effect of irbesartan on gerontal patients with hypertension and to seek its effect on endogenous creatinine clearance (Cr-c). Methods 68 gerontal patients with hypertension (Cr-c were between 50.0(19.4ml/min(1.73m 2) were randomly divided into 2 groups: irbesartan group and captopril group 34 cases per each. The values of blood pressure and Cr-c were measured before and after treatment. Results Irbesartan group and captopril group had the same antihypertensive effect on gerontal patients, but the former improved Cr-c more better than the later. There was significant difference between the two groups (P<0.01). Irbesartan group had no unproductive cough, but it was seen in captopril group (incidence was 17.6%). Conclusion Irbesartan not only has the very good antihypertensive effect but also has the effect of improvement of Cr-c and renal function.
出处 《黑龙江医学》 2003年第2期93-94,共2页 Heilongjiang Medical Journal
关键词 内科学 伊贝沙坦 老年人 高血压 内生肌酐清除率 Mcdicine Irbesartan Gerontal Hypertension Endogenous Creatinine clearance
  • 相关文献

参考文献7

  • 1[1]Markham A, Spencer C M, Jarvis B. Irbesartan:an updated review of its use in cardiovascular disorders[J].Drugs,2000,59(5):1187~1206.
  • 2[2]Mazzolai L, Maillard M, Rossat J. Angiotensin Ⅱ blockade in normotensive subject: A direct comparison of three AT1 receptor antagonists[J]. Hypertension,1999,33:S850~855.
  • 3[3]Larochelle P, Flack J M, Marbury T C, et al. Effects and tolerability of irbesartan versus enalapril in patient with severe hypertension[J].Am J Cardiol,1997,15,80(12):1613~1615.
  • 4[4]Marino M R, Langenbacher K M, Ford N F, et al.Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Moderate Hypertension[J].J Cardiovasc Pharmacol Ther,1999,4(2):67~75.
  • 5[5]Goldberg A I, Dunlay M C, Sweet C S. Safety and tolerability of losartan potassium,an angiotensin Ⅱ receptor antagonist,compared with hydrochlorothiazide, atenolol, felodipine ER and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension[J].Am J Cardiol,1995,772:793.
  • 6[6]Pechere-Bertchi A, Nussberger J, Decosterd L, et al.Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hyertensive patients[J].J Hypertens,1998,16(3):385~393.
  • 7[7]Ziai F, Ots M, Provoost A P, et al.The angiotensin recptor antagonist, irebesartan, reduces renal injury in experimental chronic renal failure[J].Kidney Int Suppl,1996,57:132~136.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部